2022年3月4日,

模量发现,Inc .波士顿,MA,东京,日本preclinical-stage computation-driven药物研发公司,关闭一系列C一轮融资的2.34日元(约20.4美元)。支持者包括绿色Coinvest投资有限合伙。,印度国家银行集团。,Heights Capital Management, Inc., and existing shareholders including UTokyo Innovation Platform Co., Ltd., JAFCO Group Co., Ltd., Keio Innovation Initiative, Inc. (KII), and Fast Track Initiative, Inc. Modulus has raised to date, a total of 5.86B JPY (approximately $51M USD). The company will use the proceeds to further its portfolio of R&D programs driven by its proprietary computational drug discovery platform and globally networked operational model. In addition to accelerating its existing pipeline of over 10 R&D programs, Modulus aims to increase its business value through expansion of its platform infrastructure, collaborations with industry and academic partners, and increase personnel in R&D and operations to deliver innovative drug candidates through clinical partnerships and additional drug discovery collaborations. Led by S. Roy Kimura, Ph.D., Co-founder and CEO, Modulus Discovery is a preclinical-stage computation-driven drug discovery company pursuing its proprietary portfolio of small-molecule discovery programs and collaborations through integration of its core biology insights, discovery platform, and scalable networked operations. Modulus is focused on the efficient delivery of medicines for patients and their families with unmet medical needs in areas including oncology, chronic inflammation / immune disorders, and rare genetic conditions. FinSMEs 04/03/2022